CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup

Background: Survival of metastatic colorectal cancer (mCRC) patients has improved, but mainly for trial patients. New predictive and prognostic biomarkers validated in the general mCRC population are needed. Caudal-type homeobox 2 (CDX2) is an intestine-specific transcription factor with potential p...

Descripción completa

Detalles Bibliográficos
Autores principales: Aasebø, Kristine, Dragomir, Anca, Sundström, Magnus, Mezheyeuski, Artur, Edqvist, Per-Henrik, Eide, Geir Egil, Ponten, Fredrik, Pfeiffer, Per, Glimelius, Bengt, Sorbye, Halfdan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026487/
https://www.ncbi.nlm.nih.gov/pubmed/32117703
http://dx.doi.org/10.3389/fonc.2020.00008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026487/
https://www.ncbi.nlm.nih.gov/pubmed/32117703
http://dx.doi.org/10.3389/fonc.2020.00008

Ejemplares similares